Liu Hong

Fourth Military Medical University, Xi’an, Liaoning, China

Are you Liu Hong?

Claim your profile

Publications (126)390.22 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Lymph nodes along the recurrent laryngeal nerves (RLN) were considered to be highly involved in ESCC patients, and radical dissection of these lymph nodes is recommended. This study aimed to demonstrate the value of thoracoscopic-laparoscopic esophagectomy (TLE) in the radical lymphadenectomy along the bilateral RLN.Methods From November 2010 to September 2012, 51 patients underwent TLE. The procedures during the radical lymphadenectomy along the bilateral RLN were done using ultrasonic scalpel with single lumen endotracheal tube intubation.ResultsThe lymph nodes along the RLN could be sufficiently removed with extremely low incidence of RLN injury. The mean number of lymph nodes removed was 3.58±2.59 along the right RLN and 2.73±1.66 along the left RLN. There were two types of the origin of right RLN, the origin of the majority was adjacent to the right subclavian artery, and the origin of three cases was away from the right subclavian artery.ConclusionsTLE in combination with single lumen tube, bilateral lung ventilation and semi-prone position could be safely and efficiently applied in radical lymphadenectomy along the bilateral RLN. Ultrasonic scalpel could be safely used in lymphadenectomy along RLN without increased heat injury of RLN.
    Surgical Practice 11/2014; · 0.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human leukocyte antigen G (HLA-G) is a non-classical HLA class I molecule thought to play a key role in maternal-fetal tolerance and cancer immune evasion. This study aimed to investigate the HLA-G expression in lesion sections and plasma sHLA-G levels of primary esophageal squamous cell carcinoma (ESCC) patients and its clinical significance in diagnosis and prognosis of ESCC. 60 ESCC patients and 28 healthy controls were recruited, and the positive expression of HLA-G in ESCC lesions and adjacent normal tissues were 70% (42/60) and 8.6% (5/60) (P<0.05), respectively, while no expression was found in normal controls. HLA-G1 and HLA-G5 were determined to be dominating isoforms measured by RT-PCR. There was a significant difference in plasma sHLA-G levels between patients with ESCC (15.04U/ml, range 4.33-250.00U/ml) and healthy controls (6.81U/ml, range 0-29.27U/ml) (P<0.01). The plasma IL-10 level was higher in ESCC patients than the controls (23.86pg/ml vs. 12.81pg/ml, P<0.01). HLA-G expression in lesion tissues was correlated with cancer cell differentiation (P=0.033), lymph node metastasis (P=0.035) of ESCC. However, no obvious correlations were demonstrated between the plasma sHLA-G levels and the clinicopathological parameters. There was a significant correlation between sHLA-G and IL-10 expression (r=0.353, P=0.006) in patients with Esophageal squamous cell carcinoma. HLA-G positive expression showed poorer prognosis of ESCC. HLA-G positive expression might serve as a potential marker in the diagnosis or prediction of ESCC.
    Immunology letters 04/2014; · 2.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Although chemotherapy is an important therapeutic strategy for gastrointestinal cancer, its clinical effect remains unsatisfied due to drug resistance. Drug resistance is a complex multistep process resulting from deregulated expression of many molecules, including tumor suppressor genes, oncogenes and microRNAs (miRNAs). A better understanding of drug resistance-related miRNAs may eventually lead to optimized therapeutic strategies for cancer patients. Areas covered: This review summarizes the recent advances of drug resistance-related miRNAs in esophageal, gastric and colorectal cancer. Furthermore, this study envisages future developments toward the clinical applications of these miRNAs to cancer therapy. Expert opinion: Drug resistance-related miRNAs may be potentially predicting biomarkers that help guide individualized chemotherapy. Specific miRNAs and their target genes can be used as therapeutic targets by reversing drug resistance. More investigations should be performed to promote the translational bridging of the latest research into clinical application.
    Expert opinion on biological therapy 04/2014; · 3.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Despite improvements in detection, surgical resection and adjuvant therapy, the prognosis of esophageal cancer (EC) patients is dismal. A number of microRNAs (miRNAs) are related with the prognosis of EC. Areas covered: This review summarises the recent advances in prognosis-related miRNAs in EC and also analyses the molecular functions that they provide. This study further envisages future developments in the potential clinical applications of these miRNAs. Expert opinion: Altered miRNA expression of cancer tissues is useful for predicting the prognosis of EC patients. Individual circulating miRNAs have the potential to be used as novel biomarkers. Continued basic studies are warranted to gain more mechanistic insights into the functional effect of prognosis-related miRNAs on EC. More clinical trials should be performed to promote the clinical use of prognosis-related miRNAs.
    Expert opinion on biological therapy 02/2014; · 3.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocellular cancer is a hypervascular cancer characterized by rapid progression as well as resistance to chemotherapy. Drug resistance arises from the alteration of many molecules, including oncogenes, tumor suppressor genes and miRNAs. This review evaluates the advances of drug resistance-related miRNAs in hepatocellular cancer, and analyzes the value of them as prognostic biomarkers and therapeutic targets. This review also discusses the limitations of miRNA-based therapy, and envisages future developments toward the clinical applications of drug resistance-related miRNAs.
    Expert review of gastroenterology & hepatology 02/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Infliximab revolutionised the treatment paradigm of Crohn's disease (CD), but did not reduce the need for surgery. The impact of biologic agents on surgical complication rates remains debated. The aim of this study was to determine the effect of preoperative infliximab use on early postoperative complications in patients with CD undergoing abdominal surgery. PubMed and Embase databases were searched to identify comparative studies that investigated postsurgical morbidity in CD patients receiving infliximab preoperatively with those not on infliximab. We used meta-analysis with random-effects model to calculate the pooled odds ratios (ORs) with 95% confidence intervals (CIs) for total complication rate as well as major, minor, infectious, and non-infectious complications. A total of 18 studies involving 5769 patients included in this systematic review. There was significant association between infliximab therapy prior to surgery and total (OR = 1.45, 95% CI 1.04-2.02; 13 studies, 2538 patients), infectious (OR = 1.47, 95% CI 1.08-1.99; 10 studies, 2116 patients) and non-infectious (OR = 2.29, 95% CI 1.14-4.61; 3 studies, 729 patients) postoperative complications respectively. There was no significant disparity in the major (OR = 1.39, 95% CI 0.85-2.27; 9 studies, 3696 patients) and minor (OR = 1.39, 95% CI 0.57-3.40; 5 studies, 753 patients) complication rates between infliximab and control groups. No publication bias was detected. Preoperative infliximab use modestly increases the risk of total early postoperative complications, and particularly infectious complications in CD patients.
    International Journal of Surgery (London, England) 01/2014; · 1.44 Impact Factor
  • Liu Hong, Yu Han, Lubi Brain
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite tremendous efforts to reduce deaths due to gastric cancer, it represents the second leading cause of cancer-related deaths worldwide. EGF receptor (EGFR) plays important roles in gastric carcinogenesis by regulation of cell cycle, angiogenesis and apoptosis. This review evaluates the functions, mechanisms and clinical uses of EGFR in gastric cancer. Although EGFR targeted single therapy shows limited effect, the combination of EGFR targeted agents with traditional chemotherapy regimens may bring about important progress in cancer therapy. More clinical trials should be performed to clarify both the prognostic and therapeutic value of EGFR in gastric cancer.
    Expert review of gastroenterology & hepatology 01/2014; 8(1):111-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background To evaluate the effect of early oral feeding on postoperative short-term outcome of gastric cancer patients receiving laparoscopic distal gastrectomy. Methods From Oct 1, 2011 to Mar 1, 2013, 84 consecutive patients with gastric cancer were involved in this retrospective study. Patients received either early oral feeding (early feeding group) or not (control group) after laparoscopic distal gastrectomy. Details concerning the postoperative outcomes and the quality of life questionnaires were collected and compared. Results Totally 40 patients were involved in the early feeding group and 44 in the control group. Demographic data were comparable in both groups. The duration of hospital stay (6.28 ± 1.26 VS 7.69 ± 1.53, P = 0.048) and time until flatus (2.06 ± 1.47 VS 3.56 ± 1.04, P = 0.044) in early feeding group were significantly less than that in control group. Furthermore, the score of fatigue scale in early feeding group on the seventh postoperative day was significantly less than that in control group (33.9 ± 12.1 VS 45.1 ± 10.7, P = 0.041). Conclusions Early oral feeding could lead to a significant improvement of the short-term benefits for patients receiving laparoscopic distal gastrectomy.
    International Journal of Surgery. 01/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gastric cancer is one of the most common cancers and accounts for a large proportion of cancer-related deaths in the world, while the pathogenesis of it is still not clear. Epigenetic changes have been found to participate in the development and progression of gastric cancer. Epigenetic changes involve methylation of cytosines in DNA, modifications of histone, chromatin remodeling, and alterations in the expression of microRNAs. MicroRNAs, a family of small non-coding RNAs, have been demonstrated to participate in many fundamental biological processes including the carcinogenesis of gastric cancer. Previous studies have shown that the downregulation of microRNAs are often caused by the methylation in the CpG islands of microRNA promoters. Here, we have summarized the functions and molecular mechanisms of gastric cancer related methylated microRNAs in gastric carcinogenesis. We further envisage the clinical application of microRNA methylation in the early diagnosis, treatment and prognosis assessment of gastric cancer.
    Digestive Diseases and Sciences 11/2013; · 2.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gastric cancer remains a leading cause of cancer-related death in the world. FGF receptor 2 (FGFR2) is preferentially amplified and overexpressed in the diffuse type of gastric cancer. This review evaluates the expression and function of FGFR2 in gastric cancer, and analyzes the use of its inhibitors for gastric cancer therapy. This review also discusses the limitations of FGFR2-based therapy, and envisages future developments toward the clinical applications of FGFR2.
    Expert review of gastroenterology & hepatology 10/2013;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The National Comprehensive Cancer Network (NCCN) recommends conservative follow-up for gastric gastrointestinal stromal tumors (GISTs) less than 2 cm. The aim of the present study was to investigate the clinical and pathological features of small gastric GISTs, re-evaluate the risk potential, and discuss the treatment strategy of small gastric GISTs. In this retrospective study, 63 cases of small gastric GISTs (less than 2 cm) were resected surgically from May 2010 to March 2013 in our department. Clinicopathological factors were collected and the malignant potential of small gastric GISTs was analyzed. The mitotic index of 14 out of 63 cases (22.22%) exceeded 5. The malignant potential of small gastric GISTs was related to tumor location (P = 0.0218). The mitotic index of 4 out of 8 GISTs (50%) located in gastric cardia exceeded 5, 8 out 28 GISTs (28.57%) located in the gastric fundus exceeded 5, and only 2 out of 27 GISTs (7.41%) located in the gastric body exceeded 5. We also discovered a good consistency between mitotic index and Ki-67 expression of small gastric GISTs. Gastric GISTs less than 2 cm also have malignant potential. Thus, we recommended surgical resection of all small gastric GISTs once diagnosed.
    World Journal of Surgical Oncology 10/2013; 11(1):273. · 1.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of esophagogastric junctional adenocarcinoma is increasing, and the surgery is associated with high mortality and morbidity rates. This study aims to evaluate whether three-field minimally invasive surgery promotes outcome as compared with three-incision open surgery. From January 1, 2009, to March 1, 2012, 114 consecutive patients with Siewert type I esophagogastric junctional adenocarcinoma were involved in this retrospective study. Patients were randomly assigned by a computer-generated randomization sequence to receive either three-incision open esophagectomy or minimally invasive esophagectomy. Details concerning patients and tumor characteristics, surgical procedures, and postoperative outcomes were collected and compared. Totally, 59 patients were involved in the open esophagectomy group and 55 in the minimally invasive esophagectomy group. The incidence of pulmonary morbidity (9.09% versus 28.81%) and vocal cord paralysis (0% versus 15.25%) in the minimally invasive group was significantly less than that in the open esophagectomy group. Furthermore, the postoperative life quality in the minimally invasive group was better than that in the open group. Survival at 2 years was 83.6% for the minimally invasive group (46 of 55 patients) and 79.7% for the open esophagectomy group (47 of 59 patients). Minimally invasive esophagectomy could lead to a significant improvement of the short-term benefits for patients with Siewert type I esophagogastric junctional adenocarcinoma.
    The Annals of thoracic surgery 08/2013; · 3.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The epidermal growth factor receptor (EGFR) plays important roles in the development of gastric cancer. This study aims to analyze the prognostic value of EGFR in patients with gastric cancer. A meta-analysis is performed by searching Cochrane Library, PubMed, EMBASE and Science Direct databases from Jan 1970 to May 2013. Data are extracted from studies evaluating the survival of gastric cancer patients with either positive or negative EGFR expression. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) are calculated. Totally 1600 cases of gastric cancer patients from five studies are subjected to final analysis. The HR of post-operational survival of patients with positive EGFR expression is 1.16 (95% CI: 0.94-1.43) as compared with those with negative expression, indicating that positive EGFR expression does not significantly predict the poor survival of gastric cancer. EGFR expression is not an independent predictor for the survival of gastric cancer patients.
    Gene 08/2013; · 2.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Drug resistance is a major clinical obstacle to the successful treatment of human cancer. The microRNAs-21 (miR-21), an oncomiR, may play an important role in the progress of drug resistance. Areas covered: This review covers all related literature on miR-21 in drug resistance of human cancers and analyzes the expression, biological functions and targets of it. This study also envisages future developments toward its clinical and therapeutic applications in cancer treatment. Expert opinion: The miR-21 may promote the drug resistance of various cancers. Inhibitors of miR-21 may function as effective approaches for reversing drug resistance in cancer cells. There is a tough way from discovering the function of miR-21 to clinical use. Further understanding of miR-21-mediated signaling pathways will help to promote the therapeutic-clinical use of miR-21 in cancer.
    Expert Opinion on Therapeutic Targets 07/2013; · 4.90 Impact Factor
  • Liu Hong, Yu Han, Lubi Brain
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Even after complete tumor removal by surgery, the clinical outcomes remain poor in patients with advanced esophageal cancer, justifying the need for new treatment options. Epidermal growth factor receptor (EGFR) is a molecular target for antibody-based therapy in various cancer types, and it may play important roles in the development of esophageal cancer. Areas covered: This review evaluates the expression, function, and mechanism of EGFR in esophageal cancer and analyzes its value for the prognosis and therapy of esophageal cancer. Future developments toward the clinical applications of EGFR to cancer treatment are also envisaged. Expert opinion: EGFR may function as an ideal therapeutic target for esophageal cancer. Further investigation of epidermal growth-factor-receptor-mediated pathways will push insight into the novel strategies of target therapy for esophageal cancer. More clinical trials should be performed to promote the success of therapeutic-clinical use of EGFR and its targets in esophageal cancer.
    Expert Opinion on Therapeutic Targets 07/2013; · 4.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to compare the quality of life in Siewert type II esophagogastric junctional adenocarcinoma patients receiving either laparoscopic total gastrectomy or open total gastrectomy. From Sep 1, 2008 to May 1, 2012, totally 204 consecutive patients with Siewert type II esophagogastric junctional adenocarcinoma were involved in this retrospective study. Patients were assigned to receive either laparoscopic total gastrectomy or open total gastrectomy. Details concerning the postoperative outcomes and the quality of life questionnaire were collected and compared. Totally 104 patients were involved in the open gastrectomy group and 100 in the laparoscopic gastrectomy group. No differences were noted between the groups in demographics, blood loss, anastomotic leak, anastomotic stricture, hospital stay, reoperation and in-hospital mortality. Totally 188 cases of patients (92.16%) responded to the questionnaire measures during the entire follow-up period, including 93 (93%) in the laparoscopic group and 95 (91.35%) in the open group. The score of every scale and item in laparoscopic group improved much more quickly comparing with the open group, suggesting that patients in laparoscopic group recovered much more quickly than those in open group. Laparoscopic total gastrectomy could lead to a significant improvement of the short-term benefits for patients with esophagogastric junctional adenocarcinoma as compared with open group.
    International Journal of Surgery (London, England) 06/2013; · 1.44 Impact Factor
  • Source
    Digestive Diseases and Sciences 05/2013; · 2.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Our previous study showed that BMP7 revealed significantly higher levels in esophageal squamous cell carcinoma (ESCC) tissues with lymph node metastasis compared with non-lymph node metastasis, using gene expression profiling assays. The roles of BMP7 in ESCC is not fully understood. AIM: The aim of this study was to investigate the effect of BMP7 on lymph node metastasis of ESCC and to explore its potential mechanism. METHODS: Expression of BMP7 in ESCC tissues was evaluated by immunohistochemistry. BMP7 were down-regulated by RNA interference. The protein and mRNA levels of BMP7 were detected by western blot and RT-PCR, respectively. High content screening and transwell assay were used to identify the metastatic ability of tumor cells. RESULTS: Positivity of BMP7 staining was 57.5 % in the tissues of primary carcinoma with lymph node metastasis compared to tissues without lymph node metastasis, and expression of BMP7 was significantly higher in the cell lines with highly metastatic capacity than that in the cell lines without metastatic ability. Suppression of endogenous BMP7 expression by siRNA in the highly metastatic cell lines resulted in significant reduction in ability of cell migration and invasion in both in vitro and in vivo studies. In addition, inhibition of BMP7 by siRNA also leads to up-regulation of E-cadherin and down-regulation of MMP-9 in the highly metastatic cell lines. CONCLUSIONS: These findings indicate that BMP7 modulates the expression of E-cadherin and MMP-9, and by which mechanism it may regulate cell migration and metastasis of ESCCs.
    Digestive Diseases and Sciences 03/2013; · 2.26 Impact Factor
  • Liu Hong, Nita Ahuja
    [Show abstract] [Hide abstract]
    ABSTRACT: Detection of colorectal cancer at an early stage may significantly decrease mortality from the disease. The current screening test of colonoscopy is of high efficacy, but its acceptance in the general public is rather low. Availability of a blood- or stool-based test of DNA methylation markers is expected to improve the screening compliance for colon cancer in the general population. The goal of this review is to describe the recent advances in DNA methylation markers of stool and blood for early detection of colon cancer, and envisage future developments toward their clinical availability. More investigations should be performed to promote both basic and clinical research of DNA methylation markers in patients with colon cancer.
    Genetic Testing and Molecular Biomarkers 02/2013; · 1.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the role of interleukin (IL)-17 in small bowel allograft rejection. We detected the expression of helper T cell 17 (Th17) cells in biopsy specimens from 3 cases of living small bowel transplantation in our department through immunofluorescence stain. We then established a rat heterotopic small bowel transplantation model. The rats were sacrificed on the 1(st), 2(nd), 3(rd), 5(th), and 7(th) d after small bowel transplantation. The degrees of transplantation rejection in rat intestine graft were examined through hematoxylin eosin (HE) stain, and the expression of Th17 cells in rat intestine graft were detected through immunofluorescence stain. In addition, the recipient rats undergoing intestinal transplantation were administrated with mouse-anti-rat IL-17 monoclonal antibody (mAb), and the survival of rats was analyzed. The recipient rats which received mouse-anti-rat IL-17 mAb treatment were sacrificed on the 1(st), 2(nd), 3(rd), 5(th), and 7(th) d after small bowel transplantation. The degrees of transplantation rejection and the expression of Th17 cells in rat intestine graft were detected through HE and immunofluorescence stain. The expression of IL-17, IL-1β, tumor necroses factor receptor-α (TNF-α), IL-6, and IL-8 in the intestine graft or serum were also detected. The expressions of Th17 cells ran parallel with the degree of acute rejection in human intestine grafts. The intestine graft rejection of rats was aggravated with prolonged duration after intestinal transplantation, and the expressions of Th17 cells were also correlated with the degree of acute rejection in rat intestine grafts. Administration of mouse-anti-rat IL-17 mAb prolonged the survival of rats after small bowel transplantation (P < 0.001). Furthermore, we found that the administration of mouse-anti-rat IL-17 mAb significantly decreased the intensity of CD4(+)IL-17(+) Th17 cells in intestine grafts on the 2(nd), 3(rd), 5(th), and the 7(th) d (97.22 ± 4.05 vs 12.45 ± 2.02 on the 7(th) d, P < 0.0001), and suppressed the severity of acute rejection. The expression of IL-17 in the intestine graft declined after mouse-anti-rat IL-17 mAb administration on the 2(nd), 3(rd), 5(th), and the 7(th) d (0.88 ± 0.03 vs 0.35 ± 0.02 on the 7(th) d, P < 0.0001). We also detected the IL-17 serum level and found that the IL-17 level reduced from the 1(st) d to the 7(th) d (6.52 ± 0.18 ng/mL vs 2.04 ± 0.15 ng/mL on the 7(th) d, P < 0.0001). No significant difference in the level of IL-17 mRNA in the intestine graft was identified between the two groups. The levels of IL-1β, TNF-α, IL-6, and IL-8 mRNA in the intestine graft after the administration of mouse-anti-rat IL-17 mAb were also tested. We found that on the 3(rd), 5(th), and 7(th) d after intestinal transplantation, administration of mouse-anti-rat IL-17 mAb significantly inhibited the levels of IL-1β (12.11 ± 1.16 vs 1.27 ± 0.15 on the 7(th) d, P < 0.001), TNF-α (27.37 ± 2.60 vs 1.06 ± 0.26 on the 7(th) d, P < 0.001), IL-6 (21.43 ± 1.79 vs 1.90 ± 0.32 on the 7(th) d, P < 0.001), and IL-8 (20.44 ± 1.44 vs 1.34 ± 0.20 on the 7(th) d, P < 0.001) mRNA in the intestine graft. IL-17 may act as a promising and potent target for inhibiting acute rejection after small bowel transplantation.
    World Journal of Gastroenterology 02/2013; 19(5):682-91. · 2.55 Impact Factor

Publication Stats

1k Citations
390.22 Total Impact Points

Institutions

  • 2004–2014
    • Fourth Military Medical University
      • • State Key Laboratory of Cancer Biology
      • • Department of Otolaryngology - Head Neck Surgery
      Xi’an, Liaoning, China
  • 2008
    • Logistical College of Chinese People's Armed Police Force
      T’ien-ching-shih, Tianjin Shi, China